Market Report Source

Overview

Report Overview

Examines the global market for aesthetic dermatologicals and specialty physician-dispensed drugs to treat conditions associated with deficits in physical image and form. Drugs such as botulinum toxins, retinoids, acid peels, 5-alpha reductase and lipase inhibitors associated with cutaneous ageing, photodamage, pigmentation defects, alopecia, and the lipodermal disorders of obesity and gynoid lipodystrophy are critically discussed to provide a detailed analysis of the high-growth market sector estimated at US$1.8 billion in 2005 and forecast to increase by 114% to US$3.9 billion by 2012. The report includes insights for product extension and optimization, sales forecasts to 2012, and impact of late-stage pipeline drugs on the market. Therapy area forecasting and illustrative market data and analysis is also presented to gain insight into top-performing products and therapy areas.

Table of Contents

CONTENTS
List of Tables
List of Figures

Executive Summary
Objectives of the Report Briefing
Research Methodology

Chapter 1 Introduction to Antiageing and Image Dermatology

Ageing and life Enhancement
What are Antiageing and Life Enhancement Pharmacotherapies?
Ageing, Lifestyle Conditions, and Dermatology

Alopecia
Prevalence of Alopecia
Alopecia as a Lifestyle Problem
The Normal Hair Growth Cycle
Types of Alopecia
Dermal Ageing
Photodamage and Solar Radiation
Pollution and Dermal Damage

Dermal Pigmentation
Hyerpigmentation and Hypopigmentation Disorders
Biological Basis to Pigmentation: Melanogenesis and Photoprotection
Cellular Mechanisms of Melanogenesis and Photoprotection
Hyperpigmentation Disorders
Hypopigmentation Disorders
Vitiligo
Albinism
Postinflammatory Hypopigmentation

Lipodermal Disorders
Gynoid Lipodystrophy
The Development of Cellulite
Treatments Options for Cellulite
Obesity
Obesity Prevalence
Types of Obesity
Measuring and Diagnosing Obesity
Aetiological Aspects of Obesity
Physiological Aspects of Hunger and Satiety
Health Risks of Obesity
Psychosocial Aspects of Obesity

Chapter 2 Image Dermatology Drug Markets

Alopecia
Alopecia Drug Market Overview
Market Forecasts for Alopecia Products
Market Analysis for the Alopecia Drug Market
Propecia (Finasteride) – Merck
Rogaine/Regaine (Minoxidil) – Pfizer
Product Extension Strategy Insights for Alopecia Products
Product Extension Strategy Insights for Finasteride
Product Extension Strategy Insights for Minoxidil
Future Considerations for Drugs to Treat Alopecia
Drug Development Prospects
BIO024 – Genaderm
Other Clinical Candidates

Cutaneous Ageing
Dermal Ageing Product Market Overview
Market Forecasts for Dermal Ageing Products
Market Analysis for Cutaneous Ageing/Photodamage Products
Market Insights and Strategies for the Botulinum Toxin Sector
Direct Competition to Botox
Botulinum Toxin Products in Asia and South America
Product Extension Strategy Insights for Botulinum Toxin Products
Market Insights and Strategies for the Topical Antiageing Product Sector
Product Extension Strategy Insights for Topical Antiageing Products
Tretinoin
Isotretinoin
Tazarotene
Idebenone
Acid Peel Products
Future Considerations and Market Insights for the Cutaneous Antiageing
Product Sector

Dermal Pigmentation Conditions
Market Forecasts for Dermal Pigmentation Products
Market Analysis of the Dermal Pigmentation Product Sector
Market Insights and Potential Product Development Strategies for Hyperpigmentation
Conditions
Hydroquinone
Tretinoin
Azelaic Acid
Market Insights and Potential Product Development Strategies for Hypopigmentation
Conditions
Induced Photoprotective Melanogenesis
Therapeutic, Prophylactic, and Cosmetic Markets for Photoprotective Melanogenesis
Solar Allergies/Polymorphous Light Eruption
Other Hypopigmentation Conditions
Skin Cancer Prophylaxis
Cosmetic-Medical Indications
Future Considerations and Market Outlook for the Dermal Pigmentation Therapy Area

Lipodermal Conditions
Gynoid Lipodystrophy (Cellulite)
Novel Pharmacotherapeutics for Cellulite
BIO303 – Enhance Biotech/Bioaccelerate
Phosphatidylcholine (Lecithin)
Redeveloping Old Molecules for New Cosmetic Indications
Obesity
Market Analysis for Antiobesity Drugs
Market Forecasts for Antiobesity Drugs
Antiobesity Product Extension Strategies and Insights
Sibutramine – (Meridia/Reductil) Abbott Laboratories
Market Outlook for Sibutramine
Orlistat
Class Competition – ATL-962 (Cetilistat) Alizyme
Product Extension Strategy Insights for Orlistat
Antiobesity Drugs at the Premarket Authorization Stage
Rimonabant
Safety and Efficacy Data
Lipodermal Disorders – Future Considerations and Market Insights
Gynoid Lipodystrophy
Obesity
Emerging Weight Regulation and Lipid Metabolism Market Opportunities
Appetite Stimulation
Lipodystrophies

Chapter 3 Drugs in Research and Development
Introduction

Alopecia
Research and Development Overview
Hedgehog Agonists – Curis
ICX-TRC – Intercytex
BIO024 – Genaderm/Bioaccelerate

Dermal Ageing
Research and Development Overview
Dysport/Reloxin – Ipsen/Inamed
Autologous Cell Therapy – Isolagen
17-Beta Oestradiol (E2) – University of Michigan/Pfizer

Pigmentation Conditions
Research and Development Overview
EPT1647 – Epitan

Lipodermal Conditions
Gynoid Lipodystrophy
Research and Development Overview
BIO303 – Enhance Biotech/Bioaccelerate

Obesity
Research and Development Overview

Chapter 4 Market Analysis, Therapy Forecasting, and Prospect Mining

Introduction: Data Analysis, Therapy Forecasting, and Prospect Mining
Market Analysis and Therapy Forecasting
Dermatology: Alopecia, Dermal Ageing, Pigmentation Disorders and
Lipodermal Conditions
Therapy Area Forecasts
Market Share of Dermatological Therapy Areas

Comparative Analysis: Product Sales
Dermatology Therapy Areas

Prospect Mining
Dermatological Drug Prospects in the Antiageing and Life Enhancement
Therapy Market
Alopecia
Dermal Ageing
Dermal Pigmentation
Lipodermal Conditions

Chapter 5 Report Synopsis

Dermatology
Alopecia – Key Data Points
Dermal Ageing and Pigmentation Disorders – Key Data Points
Lipodermal Conditions – Key Data Points

Bibliography and Reference Sources

List of Tables
Table 1.1 Types of Alopecia
Table 1.2 Features of Intrinsic Chronological Cutaneous Ageing and
Photoageing
Table 1.3 Factors Associated with Dermal Ageing
Table 1.4 Types of Solar Radiation
Table 1.5 Common Hyperpigmentation Disorders
Table 1.6 Types of Hypopigmentation Disorders
Table 1.7 Calculating Body Mass Index
Table 1.8 Aetiological Factors Associated with Obesity
Table 1.9 Health Risks and Comorbidities Associated with Obesity
Table 1.10 Psychological, Behavioural, and Socioenvironmental Factors
Associated with Obesity
Table 2.1 Estimated Global Sales & Forecasts of Drugs for Alopecia (US$m),
2004-2012
Table 2.2 Estimated Global Sales & Forecasts of Dermal Antiageing Products,
2004-2012
Table 2.3 Topical Antiageing/Photodamage Products, 2005
Table 2.4 Estimated Global Sales & Forecasts of Products for Pigmentation
Conditions, 2004-2012
Table 2.5 Pharmaceutical Products to Treat Common Dermal Pigmentation, 2005
Table 2.6 Estimated Global Sales & Forecasts of Antiobesity Drugs, 2004-2012
Table 3.1 Drugs in Development for Alopecia, 2005
Table 3.2 Drugs in Development for Dermal Ageing, 2005
Table 3.3 Drugs in Development for Pigmentation Disorders, 2005
Table 3.4 Drugs in Development for Gynoid Lipodystrophy (Cellulite), 2005
Table 3.5 Drugs in Development for Obesity, 2005
Table 3.6 Drugs in Development for Appetite Stimulation and Lipodystrophy, 2005
Table 4.1 Global Drug Market for Dermatological Conditions Associated with Ageing
and Lifestyle Dysfunction (US$m), 2004-2012

List of Figures
Figure 1.1 Factors Involved in Normal Body Weight Regulation
Figure 2.1 Projected Growth Rates for Alopecia Drugs, 2005-2012
Figure 2.2 Estimated Global Sales of Alopecia Drugs, 2004-2012
Figure 2.3 Projected Growth Rates for Cutaneous Antiageing Products,
2005 & 2012
Figure 2.4 Estimated Global Sales of Dermal Antiageing Products, 2004-2012
Figure 2.5 Projected Growth Rates of Products for Pigmentation Conditions,
2005 & 2012
Figure 2.6 Estimated Global Sales of Products for Pigmentation Conditions,
2004-2012
Figure 2.7 Projected Growth Rates of Current Antiobesity Drugs, 2005-2012
Figure 2.8 Estimated Global Sales of Antiobesity Drugs, 2004-2012
Figure 2.9 Main Drivers of Growth in the Antiobesity Pharmacotherapeutic
Market
Figure 4.1 Dermatological Therapy Area Forecasts, 2005 & 2012 (US$m)
Figure 4.2 Market Share of Dermatological Therapy Areas, 2005 & 2012
Figure 4.3 Comparative Analysis of Leading Dermatology Products, 2004-2012 (US$m)
Figure 4.4 Key Alopecia Drug Prospects in the Antiageing and Life
Enhancement Development Pipeline, 2005
Figure 4.5 Key Dermal Ageing Prospects in the Antiageing and Life
Enhancement Development Pipeline, 2005
Figure 4.6 Key Dermal Pigmentation Drug Prospects in the Antiageing and
Life Enhancement Development Pipeline, 2005
Figure 4.7 Key Lipodermal Drug Prospects in the Antiageing and Life
Enhancement Development Pipeline, 2005